

Product name

Catalog

number

POLATUZUMAB

1 OLATOZOWA

POZ10211

Product description

POLATUZUMAB:

Polatuzumab is a humanized monoclonal IgG1 specific for human CD79b.

mAb sequence

Heavy chain

>Polatuzumab_HC

EVQLVESGGGLVQPGGSLRLSCAASGYTFSSYWIEWVRQAPGKGLEWIGEILPGGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTRRVPIRLDYWGQGTLVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP QVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

Light Chain

>Polatuzumab_LC

DIQLTQSPSSLSASVGDRVTITCKASQSVDYEGDSFLNWYQQKPGKAPKLLIYAASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSNEDPLTFGQGTKVEIKRTVAAPS VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Product features and protocols

Key features

1	Purity	>95% as determined by SDS-PAGE
2	Labelling	Arg- ¹³ C ₆ , ¹⁵ N ₄ Lys- ¹³ C ₆ , ¹⁵ N ₂

3 Isotopic >99% incorporation as dete

as determined by LC-MS/MS analysis of digested SIL-mAb

Other features

Expression System	CHO cell line
Protein content	Quantitation is carried out by UV Absorbance at 280 nm
Formulation	9.3 mM Succinic acid 12.6 mM NaOH 8.61 % Sucrose pH 5.3

Product preparation

For product preparation we recommend the following steps:

- 1. Briefly centrifuge the tube before opening
- 2. Reconstitute by adding the appropriate volume of ultrapure water for a final concentration of 200 μ g/ml (e.g. 50 μ l for 10 μ g or 250 μ l for 50 μ g)
- 3. Vortex gently to insure complete dissolution
- 4. Wait 15 minutes at Room temperature before proceeding further
- 5. Vortex gently again and centrifuge briefly

Product storage

The product is lyophilized and shipped at room temperature. **Store at -80 °C upon receipt.**

After reconstitution, the protein can be preserved at 4°C for a few weeks.

Avoid multiple freeze-thaw cycles







How to use our product



SIL mAbs allow to overcome the process variability since they are added at the very beginning of a sample preparation. This has positive impact on your analyte quantification, especially if the analyte interacts with other species commonly present within the matrix (1).



Supporting information



References

1. G.Picard, D. Lebert, et al. PSAQ standards for accurate MS-based quantification of proteins: from the concept to biomedical applications, J. Mass Spectrom. 2012, 47, 1353-1363

SDS-PAGE gel analysis of **POLATUZUMAB** protein in non-reducing/ non heated conditions (NR/NH).
Stained with Coomassie blue



The product is intended for research use only. Not for diagnostic or therapeutic use.

Legal

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.